A new injection is approved for opioid overdose; The Advisory Committee on Immunization Practices releases vaccine schedules; The FDA provides a list of approved COVID-19 tests; A trial of an investigational spontaneous urticaria treatment is stopped; And the first condom is authorized for anal intercourse.

This week in COVID related news, a heartburn medication shows benefit in patients; Bebtelovimab is authroized; Veklury is shown to retain antiviral activity against variants. Away from COVID, a functionally scored carbidopa/levodopa tablet is now available for Parkinson disease, and the FDA issue a ketamine compounding warning.

This week: news of millions of courses of a COVID-19 oral antiviral being provided to the US government for distribution throughout the country; There's a draft guidance for novel nonopioid analgesics; Possible strangulation warning for enteral feeding tubes; A new treatment has been approved for cold agglutinin disease; And a treatment is under review for HFrEF.

This week: The approval of a second COVID-19 vaccine; Pfizer and BioNTech submit for Emergency use of their vaccine for children under 5; Pfizer have also stopped development on a potential drug treatment to reduce cardiovascular risk and severe hypertriglyceridemia; And new dosing options for a HIV drug.

Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; New data produces a reconsideration for Pepaxto withdrawal; And there's a new treatment approval for unresectable or metastatic uveal melanoma.

This week we have news of two new approval for atopic dermatitis; Warnings around counterfeit HIV treatments; Zydelig indications withdrawn; CDC pediatric influenza vaccine study results; And an FDA warning against a particular brand of COVID-19 antibody tests.

This week: Novel insomnia treatment; The FDA comment on magnesium hypertension claim; Transmucosal buprenorphine linked to dental decay; Researchers assess changes in menstrual cycle in relation to COVID vaccines; And experts have their say on the best diets for 2022.

Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis.

This week we bring you up to speed on a lot of COVID-related news, despite the emergence of Omicron, there is positive news; Evusheld has become the first pre-exposure prophylaxis for COVID-19; Data shows that the Pfizer-BioNTech booster dose offers protection against Omicron; Monoclonal antibody therapy is authorized for kids; Heterologous boosting may be more beneficial than homogeneous; and important info about some Veklury lots being recalled.

We made it to 100! This week Pfizer seeks Emergency Use Authorization for their COVID oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.